KARACHI, July 12 — For patients and researchers navigating the complex terrain of artificial intelligence, a familiar name from the social media world has quietly become a major force in open-source AI. Meta’s family of Llama large language models, first released in February 2023, represents one of the most significant shifts in how advanced AI tools reach developers, companies, and potentially, the healthcare sector. The story begins in early 2023, when Meta released its first Llama model.
Unlike competitors such as OpenAI and Google, which kept their most powerful models behind closed doors, Meta chose a different path. The company made Llama open-source, meaning developers anywhere in the world could download the underlying code, modify it, and build their own applications.
This was not a small decision. It was a strategic bet that openness, rather than exclusivity, would win the long game.
A rapid evolution
Meta did not stop with one release. Llama 2 followed in July 2023, and Llama 3 arrived in July 2024. By August 2024, the company introduced Llama 3.1, a model with 405 billion parameters — making it one of the largest open-source models available.
To put that in context, a model’s parameter count is a rough measure of its capacity to learn and generate complex responses. A model of this size can handle tasks that require deep reasoning, summarisation, and even basic analysis of medical literature.
The open-source strategy has clearly resonated with the developer community. As of March 2025, Llama 3 had been downloaded over 350 million times on Hugging Face, a popular platform for sharing machine learning models. Those numbers are not just a vanity metric.
They represent real adoption by startups, academic researchers, and enterprises who want to customise AI without being locked into a single vendor’s ecosystem.
Building an ecosystem
The encouraging part for those watching this space is what those download numbers mean for innovation. By making Llama freely available, Meta has attracted AI talent and fostered a developer ecosystem around its models. Analysts say this strengthens Meta’s position in enterprise AI, a market where trust, transparency, and customisation matter.
In healthcare, for example, an open-source model can be fine-tuned on specific clinical data sets, audited for bias, and deployed in settings where patient privacy demands local, not cloud-based, processing. Meta’s own platforms have also felt the impact.
The company reported that Llama-powered AI tools on Facebook and Instagram reached 400 million monthly active users by December 2024. That is a substantial user base, and it gives Meta real-world feedback on how these models perform at scale.
The open-source argument
Mark Zuckerberg, Meta’s chief executive, has argued that open-source AI will become the industry standard. This stance has resonated with investors who see long-term growth potential in a model that is not controlled by a single gatekeeper. For patients and doctors, the implications are worth watching.
Open-source models can be inspected, tested, and improved by the global research community — a process that mirrors the peer-review tradition in medicine. If an AI tool makes a recommendation about a treatment plan, clinicians need to understand why.
Open-source code makes that transparency possible in a way that proprietary black boxes do not. That said, early findings suggest caution is still warranted. Large language models, even open-source ones, can produce convincing but incorrect information.
They do not truly understand biology or medicine; they pattern-match on vast amounts of text. Patients should always talk to their doctor before acting on any AI-generated health advice.
The technology is a tool, not a replacement for clinical judgment.
What to watch next
As of mid-2026, the Llama family continues to evolve. The trajectory is clear: more parameters, broader adoption, and deeper integration into the tools that researchers and clinicians use daily. The open-source approach has already changed how the AI industry thinks about access and collaboration.
Whether that translates into measurable improvements in patient outcomes is a question that will take years to answer. For now, the message for patients and healthcare professionals is one of measured hope.
The technology is advancing rapidly, and its open nature invites scrutiny and improvement. But as with any new tool in medicine, the responsible path is to proceed with evidence, consult your doctor, and keep asking questions.
